WE-FG-206-07: Assessing the Lung Function of Patients with Non-Small Cell Lung Cancer Using Hyperpolarized Xenon-129 Dissolved-Phase MRI

2016 ◽  
Vol 43 (6Part42) ◽  
pp. 3832-3832 ◽  
Author(s):  
K Qing ◽  
J Mugler ◽  
Q Chen
Keyword(s):  
Lung Cancer ◽  
Lung Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Hyperpolarized Xenon ◽  
Dissolved Phase

scholarly journals Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xiyue Zhang ◽  
Wei Li ◽  
Chunyan Li ◽  
Jie Zhang ◽  
Zhenzhong Su
Keyword(s):  
Lung Cancer ◽  
Lung Function ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
High Resolution Computed Tomography ◽  
Chemotherapeutic Regimen

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unclear pathogenesis. IPF is considered as a risk factor for lung cancer. Compared to other lung cancers, small-cell lung cancer (SCLC) has a lower incidence, but has a more aggressive course. Patients with IPF and SCLC have a lower survival rate, more difficult treatment, and poorer prognosis. Case presentation Case 1 was of a 66-year-old man with IPF for 5 years, who was admitted to our hospital for dyspnea. Case 2 was of a 68-year-old woman, who presented with chest pains, cough, and dyspnea. Both patients had extremely poor lung function. High-resolution computed tomography and pathology revealed that both patients had IPF and SCLC. Chemotherapy comprising nedaplatin (80 mg/m2) and etoposide (100 mg for 5 days) was initiated for both patients. Antifibrotic agents were continued during the chemotherapeutic regimen. Both patients showed improvement in their condition after treatment. Conclusion The favorable outcomes in these 2 cases suggests that chemotherapy is worth considering in the management of patients having SCLC and IPF with poor lung function.

Effects of radiotherapy and chemotherapy on lung function in patients with non–small-cell lung cancer

2003 ◽  
Vol 56 (1) ◽  
pp. 114-120 ◽  
Author(s):  
Ramesh Gopal ◽  
George Starkschall ◽  
Susan L Tucker ◽  
James D Cox ◽  
Zhongxing Liao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Thoracoscopic lobectomy for non-small-cell lung cancer in patients with impaired pulmonary function: analysis from a national database

2020 ◽  
Vol 30 (6) ◽  
pp. 803-811
Author(s):  
Stefano Bongiolatti ◽  
Alessandro Gonfiotti ◽  
Eduart Vokrri ◽  
Sara Borgianni ◽  
Roberto Crisci ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Function ◽  
Pulmonary Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
National Database ◽  
Small Cell Lung ◽  
Increased Risk ◽  
Impaired Lung Function

Abstract OBJECTIVES The objective of this retrospective multi-institutional study was to evaluate the postoperative outcomes of video-assisted thoracoscopic surgery (VATS)-lobectomy (VATS-L) for non-small-cell lung cancer (NSCLC) in patients with impaired lung function. The second end point was to illustrate the effective role of forced expiratory volume in 1 s (FEV1%) and the diffusing capacity of the lung for carbon monoxide (DLCO%) in predicting complications in this population. METHODS Data from patients who underwent VATS-L at participating centres were analysed and divided into 2 groups: group A comprised patients with FEV1% and/or DLCO% >60% and group B included patients with impaired lung function defined as FEV1% and/or DLCO% ≤60%. To define clinical predictors of death and complications, we performed univariate and multivariable regression analyses. RESULTS A total of 5562 patients underwent VATS-L, 809 (14.5%) of whom had impaired lung function. The postoperative mortality rate did not differ between the 2 groups (2.3% vs 3.2%; P = 0.77). The percentage of patients who had any complication (21.4% vs 34.2%; P ≤ 0.001), the complication rate (28% vs 49.8%; P ≤ 0.001) and the length of hospital stay (P ≤ 0.001) were higher for patients with limited pulmonary function. Impaired lung function was a strong predictor of overall and pulmonary complications at multivariable analysis. CONCLUSIONS VATS-L for NSCLC can be performed in patients with impaired lung function without increased risk of postoperative death and with an acceptable incidence of overall and respiratory complications. Our analysis suggested that FEV1% and DLCO% play a substantial role in estimating the risk of complications after VATS-L, but their role was less reliable for estimating the mortality.

THE RELATIONSHIP BETWEEN LUNG FUNCTION AND NON- SMALL CELL LUNG CANCER IN MEN AND WOMEN

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 169S
Author(s):  
Samir Malhotra ◽  
Stephen Lam ◽  
S.F.P. Man ◽  
Wei Q. Gan ◽  
Don D. Sin
Keyword(s):  
Lung Cancer ◽  
Lung Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Men And Women ◽  
The Relationship

Preserving Middle Lobe to Improve Lung Function in Non-Small-Cell Lung Cancer

2009 ◽  
Vol 17 (2) ◽  
pp. 153-156 ◽  
Author(s):  
Corinna Ludwig ◽  
Philippe Morand ◽  
Jost Schnell ◽  
Erich Stoelben
Keyword(s):  
Lung Cancer ◽  
Lung Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Middle Lobe ◽  
Small Cell ◽  
Improve Lung Function ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document